The requirements for several listed medicine ingredients have been revised, necessitating compliance with new permissible ingredients and updated safety requirements.
These changes affect the formulation and safety compliance obligations for sponsors of listed medicines, impacting product availability and market adherence.
Sponsors must align their products with the updated safety and formulation requirements for permissible ingredients as per the new determination.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Addition of new permissible ingredients and update of safety requirements/restrictions for existing ingredients in the Therapeutic Goods Determination.
Sponsors of listed medicines must ensure that their products comply with the updated safety and formulation requirements for permissible ingredients.
Sponsors must align their products with the updated safety and formulation requirements for permissible ingredients as per the new determination.
The TGA has updated the Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2026, implementing new permissible ingredients and modifying safety requirements for existing ones. Sponsors of listed medicines must now ensure compliance with these updated safety and formulation standards.
What changed: The requirements for several listed medicine ingredients have been revised, necessitating compliance with new permissible ingredients and updated safety requirements.
Why it matters: These changes affect the formulation and safety compliance obligations for sponsors of listed medicines, impacting product availability and market adherence.
Practical implication: Sponsors must align their products with the updated safety and formulation requirements for permissible ingredients as per the new determination.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
